Scientific Advisory Board
Douglas Cameron, co-president and director of First Green Partners, a Minneapolis-based early-stage investment company.
Douglas is the former head of biotechnology at Cargill where he built and led Cargill’s corporate biotechnology research group. He was the Managing Director-Chief Scientific Advisor at Piper Jaffray and Chief Scientific Officer at Khosla Ventures. Prior to his industry roles, he was a professor of chemical engineering at the University of Wisconsin-Madisonwere he taught biochemical engineering and established a leading research laboratory in the areas of metabolic engineering and bioprocess technology.
Jay Keasling, co-founder of a number of startups in this space, including Amyris (NASDAQ: AMRS), one of the most recognised names in commercial synthetic biology.
He is a professor in the Department of Chemical & Biomolecular Engineering and the Department of Bioengineering, Senior Faculty Scientist and Associate Laboratory Director for Biosciences at Lawrence Berkeley National Laboratory, and Chief Executive Officer of the Joint BioEnergy Institute. The Keasling group is perhaps best known for its contributions to the development of a synthetic biology technique for producing the anti-malaria treatment artemisinin in yeast — at a fraction of the cost of plantation-derived artemisinin.
Karl-Heinz Altmann, ETH Zürich.
Prof. Karl-Heinz Altmann studied chemistry at the University of Mainz, Germany, and he holds a Ph. D. in organic chemistry from the University of Basel, Switzerland. Since 2003 he is Full Professor of Pharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH) in Zürich, Switzerland. Before 2003, he had spent 13 years in drug discovery research at Novartis Pharma, where he was the Senior Scientific Expert for Chemistry (2000- 2002) and the acting Global Head of Discovery Chemistry (2003). Prof. Altmann’s research interests are at the interface between chemistry and biology, with a particular focus on the chemical synthesis of biologically active natural products and their synthetic and semi-synthetic analogs.
Karsten Kristiansen, Head of Department of Biology, University of Copenhagen.
Karsten Kristiansen is Professor of Molecular Biology and Head of the Department of Biology, University of Copenhagen. He was previously Professor at the Department of Biochemistry and Molecular Biology, University of Southern Denmark, where he was head of department from 1992 to 2005. He was a co-founder of BioLigands ApS and served as CEO from 2002-2007. After graduation from the University of Copenhagen, he held postdoctoral positions at the Max-Planck-Institut für Molekulare Genetik in Berlin and at the Institut de Biologie Physico-Chimique, Fondation Edmond de Rothschild, in Paris. He is member of the Danish Academy of Natural Sciences and visiting professor at the Beijing Genomics Institute. His research focuses on regulation of gene expression and cellular differentiation with particular emphasis on lipid signalling and the effects of natural compounds.